VIEWS: 8 PAGES: 2 CATEGORY: Medicine POSTED ON: 6/3/2010
A global leader in serving libraries of all types, ProQuest LLC (“ProQuest”) supports the breadth of the information community with innovative discovery solutions that power the business of books and the best in research experience. More than a content provider or aggregator, ProQuest is an information partner, creating indispensable research solutions that connect people and information. Through innovative, user-centered discovery technology, ProQuest offers billions of pages of global content that includes historical newspapers, dissertations, and uniquely relevant resources for researchers of any age and sophistication—including content not likely to be digitized by others.
000A20_MPR_1208.qxp 11/21/2008 5:03 PM Page 1 NEW PRODUCTS THIS QUARTER Alvesco (from Sepracor) a ciclesonide Rotarix (from GlaxoSmithKline) a live, metered-dose inhaler as prophylactic attenuated human G1P rotavirus oral therapy for the maintenance treatment vaccine, for the prevention of rotavirus of asthma in patients ≥12 years of age— gastroenteritis caused by G1 and non-G1 Section 18A types (G3, G4, and G9) in infants and children— Section 10A Cleviprex (from The Medicines Company) an intravenous calcium channel blocker, TussiCaps (from Mallinckrodt) a hydroco- for the reduction of blood pressure in done/chlorpheniramine extended-release adults when oral therapy is not feasible capsule for the relief of cough and upper or desirable in adults—Section 2A respiratory symptoms—Section 18C For more New Products visit www.PrescribingReference.com. PIPELINE Cardiovascular POT-4 (from Potentia) a complement ADX415 (from Addrenex) a centrally inhibitor being investigated for the treat- acting, alpha-2 receptor agonist being eval- ment of age-related macular degeneration uated for the treatment of hypertension— (AMD)—Phase 1 Phase 2 Gastrointestinal tract CNS Linaclotide (from Ironwood and Forest Carisbamate (Comfyde, from Johnson & Laboratories) an oral guanylate cyclase Johnson) an investigational compound type-C receptor agonist being studied for being developed for the adjunctive treat- the treatment of irritable bowel syndrome ment of partial onset seizures in patients with constipation (IBS-C)—Phase 2 ≥16 years of age—NDA submitted
Pages to are hidden for
"PIPELINE 000A20 MPR 1208"Please download to view full document